Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Addit...

Descripción completa

Detalles Bibliográficos
Autores principales: Miskoff, Jeffrey A, Chaudhri, Moiuz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Family/General Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126779/
https://www.ncbi.nlm.nih.gov/pubmed/30197847
http://dx.doi.org/10.7759/cureus.2924
Descripción
Sumario:Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We present a case of a 50-year-old male with a prolonged survival and a past medical history of prostate and lung cancer.

Ejemplares similares